These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 17317844

  • 1. Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.
    Manara MC, Landuzzi L, Nanni P, Nicoletti G, Zambelli D, Lollini PL, Nanni C, Hofmann F, García-Echeverría C, Picci P, Scotlandi K.
    Clin Cancer Res; 2007 Feb 15; 13(4):1322-30. PubMed ID: 17317844
    [Abstract] [Full Text] [Related]

  • 2. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
    Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, Croci S, Perdichizzi S, Zambelli D, Serra M, García-Echeverría C, Hofmann F, Picci P.
    Cancer Res; 2005 May 01; 65(9):3868-76. PubMed ID: 15867386
    [Abstract] [Full Text] [Related]

  • 3. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
    Tanno B, Mancini C, Vitali R, Mancuso M, McDowell HP, Dominici C, Raschellà G.
    Clin Cancer Res; 2006 Nov 15; 12(22):6772-80. PubMed ID: 17121898
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis.
    Moser C, Schachtschneider P, Lang SA, Gaumann A, Mori A, Zimmermann J, Schlitt HJ, Geissler EK, Stoeltzing O.
    Eur J Cancer; 2008 Jul 15; 44(11):1577-86. PubMed ID: 18445520
    [Abstract] [Full Text] [Related]

  • 5. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
    Maiso P, Ocio EM, Garayoa M, Montero JC, Hofmann F, García-Echeverría C, Zimmermann J, Pandiella A, San Miguel JF.
    Br J Haematol; 2008 May 15; 141(4):470-82. PubMed ID: 18341634
    [Abstract] [Full Text] [Related]

  • 6. Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin.
    Adachi Y, Li R, Yamamoto H, Min Y, Piao W, Wang Y, Imsumran A, Li H, Arimura Y, Lee CT, Imai K, Carbone DP, Shinomura Y.
    Carcinogenesis; 2009 Aug 15; 30(8):1305-13. PubMed ID: 19493905
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells.
    Benini S, Manara MC, Baldini N, Cerisano V, Massimo Serra, Mercuri M, Lollini PL, Nanni P, Picci P, Scotlandi K.
    Clin Cancer Res; 2001 Jun 15; 7(6):1790-7. PubMed ID: 11410521
    [Abstract] [Full Text] [Related]

  • 8. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.
    Höpfner M, Baradari V, Huether A, Schöfl C, Scherübl H.
    Endocr Relat Cancer; 2006 Mar 15; 13(1):135-49. PubMed ID: 16601284
    [Abstract] [Full Text] [Related]

  • 9. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.
    Gotlieb WH, Bruchim I, Gu J, Shi Y, Camirand A, Blouin MJ, Zhao Y, Pollak MN.
    Gynecol Oncol; 2006 Feb 15; 100(2):389-96. PubMed ID: 16300820
    [Abstract] [Full Text] [Related]

  • 10. Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma.
    Sturla LM, Westwood G, Selby PJ, Lewis IJ, Burchill SA.
    Cancer Res; 2000 Nov 01; 60(21):6160-70. PubMed ID: 11085540
    [Abstract] [Full Text] [Related]

  • 11. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
    Cunningham MP, Thomas H, Marks C, Green M, Fan Z, Modjtahedi H.
    Int J Oncol; 2008 Nov 01; 33(5):1107-13. PubMed ID: 18949375
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications.
    Girnita L, Wang M, Xie Y, Nilsson G, Dricu A, Wejde J, Larsson O.
    Anticancer Drug Des; 2000 Feb 01; 15(1):67-72. PubMed ID: 10888037
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
    Beltran PJ, Chung YA, Moody G, Mitchell P, Cajulis E, Vonderfecht S, Kendall R, Radinsky R, Calzone FJ.
    J Pharmacol Exp Ther; 2011 Jun 01; 337(3):644-54. PubMed ID: 21385891
    [Abstract] [Full Text] [Related]

  • 14. NVP-BEZ235 as a new therapeutic option for sarcomas.
    Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, Lollini PL, Maira SM, García-Echeverría C, Mercuri M, Picci P, Scotlandi K.
    Clin Cancer Res; 2010 Jan 15; 16(2):530-40. PubMed ID: 20068094
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling.
    Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL, Astolfi A, Pandini G, López-Guerrero JA, Schaefer KL, Belfiore A, Picci P, Scotlandi K.
    Oncogene; 2011 Jun 16; 30(24):2730-40. PubMed ID: 21278796
    [Abstract] [Full Text] [Related]

  • 16. Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells.
    Strammiello R, Benini S, Manara MC, Perdichizzi S, Serra M, Spisni E, Picci P, Scotlandi K.
    Horm Metab Res; 2003 Jun 16; 35(11-12):675-84. PubMed ID: 14710346
    [Abstract] [Full Text] [Related]

  • 17. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice.
    Scotlandi K, Benini S, Nanni P, Lollini PL, Nicoletti G, Landuzzi L, Serra M, Manara MC, Picci P, Baldini N.
    Cancer Res; 1998 Sep 15; 58(18):4127-31. PubMed ID: 9751624
    [Abstract] [Full Text] [Related]

  • 18. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target.
    Scotlandi K, Benini S, Sarti M, Serra M, Lollini PL, Maurici D, Picci P, Manara MC, Baldini N.
    Cancer Res; 1996 Oct 15; 56(20):4570-4. PubMed ID: 8840962
    [Abstract] [Full Text] [Related]

  • 19. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions.
    Scotlandi K, Manara MC, Strammiello R, Landuzzi L, Benini S, Perdichizzi S, Serra M, Astolfi A, Nicoletti G, Lollini PL, Bertoni F, Nanni P, Picci P.
    J Clin Oncol; 2003 May 15; 21(10):1952-60. PubMed ID: 12743148
    [Abstract] [Full Text] [Related]

  • 20. Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy.
    Zhou Z, Bolontrade MF, Reddy K, Duan X, Guan H, Yu L, Hicklin DJ, Kleinerman ES.
    Clin Cancer Res; 2007 Aug 15; 13(16):4867-73. PubMed ID: 17699866
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.